{"page":{"totalFilteredElements":327},"studies":[{"active":true,"description":"Patientendatenintegrationsplattform der Pancreatic Cancer Alliance Bavaria (PCAB)","eudractNumber":null,"id":10521,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-05-26T14:08:12+02:00","shortTitle":"PCAB (Pankreasregister)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":9703,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-03-15T09:44:27+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":10857,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-04-01T12:49:15+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":10618,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-08-05T12:16:13+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":4239,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-07-01T11:56:58+02:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774<br /></div>","eudractNumber":null,"id":4571,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-12-02T08:31:51+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prostate Cancer Outcomes &#8211; Compare &amp; Reduce Variation in&#160; DKG - zertifizierten&#160; Prostatakrebszentren<br /><div><br /></div><div>DRKS00010774</div>","eudractNumber":null,"id":4307,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-01-03T10:38:27+01:00","shortTitle":"PCO-D Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Pr&#228;vention von fr&#252;hen Darmkrebserkrankungen - PEARL","eudractNumber":null,"id":11520,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05541601","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-10-10T08:31:53+02:00","shortTitle":"PEARL","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"An Epidemiological, Prospective Cohort Study to Generate Real-world Evidence in Patients with HR*/HER2- Advanced Breast Cancer Treated in the First-line Setting as per Current Standard of Care with an Endocrine-based Palbociclib Combination Therapy","eudractNumber":null,"id":6466,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"CDK (Cyclin-Dependent Kinase)","id":"mt_205"},{"name":"CDK 4/6","id":"mt_26"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"CDK4","id":"mt_131"},{"name":"CDK6","id":"mt_176"}],"nctNumber":"NCT04767594","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2020-11-26T13:03:14+01:00","shortTitle":"PERFORM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications. (PHOEBUS)","eudractNumber":"2022-501831-18","id":11222,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2025-11-27T13:57:47+01:00","shortTitle":"PHOEBUS - MPOH08","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}